AliveCor Partners with LifeWatch to Expand Into Remote Patient
**SAN FRANCISCO, Calif. January 12, 2016– **AliveCor, Inc., the leader in FDA-cleared ECG technology for mobile devices, announced today a strategic partnership with LifeWatch AG (SIX Swiss Exchange: LIFE), a leading developer of medical solutions and remote diagnostic monitoring services to the digital health market. The AliveCor Mobile ECG will now be integrated into LifeWatch’s remote cardiac monitoring service, AliveCor’s first step into remote patient monitoring.
Remote monitoring with the FDA cleared AliveCor Mobile ECG outside of the care setting, will allow care providers to remotely monitor and manage their patients while also providing patients the peace of mind to see what is going on with their heart health in real time. This can potentially lessen the burden on the health care system, enable healthcare providers to monitor high-risk patients, and help patients retain their independence and control over their heart health.
“We are excited about expanding into the remote patient monitoring market, which will allow us to have a bigger impact on people’s lives and bring healthcare into the 21^st^ century,” said Vic Gundotra, chief executive officer of AliveCor. “Using the AliveCor Mobile ECG will keep patients in touch with their physicians outside of the hospital and can help to identify cardiac problems before something life-threatening occurs.”
“Digital health monitoring is revolutionizing how people interact with healthcare delivery. The AliveCor Mobile ECG will enable LifeWatch to broaden its cardiac event monitoring services, whilst at the same time opening the door to post-event cardiac monitoring via a patient’s own mobile device,” said Dr. Stephan Rietiker, CEO of LifeWatch.
The AliveCor® Mobile ECG is intended to record, store and transfer single-channel ECG rhythms. The AliveCor Mobile ECG also displays ECG rhythms and detects the presence of atrial fibrillation and normal sinus rhythm (when prescribed or used under the care of a physician). The AliveCor Mobile ECG is intended for use by healthcare professionals, patients with known or suspected heart conditions and health conscious individuals. The device has not been tested for and it is not intended for pediatric use. The AliveCor Mobile ECG is compatible with all iOS and most Android OS mobile devices. With secure storage in the cloud, users have the ability to access their data confidentially anytime, anywhere.
For more information on where to buy your AliveCor Mobile ECG please visit store.alivecor.com.
About AliveCor, Inc.
AliveCor, Inc., is recognized around the world for transforming cardiac care. The FDA cleared AliveCor® Mobile ECG is the most clinically validated mobile ECG monitor on the market. It is recommended by leading cardiologists and used by people worldwide for accurate ECG recordings. Today, we offer a simple to use mobile device and service providing instant analysis for detecting atrial fibrillation (AFib) and normal ECG’s. AliveCor is a privately-held company headquartered in San Francisco, Calif. For more information, please visit www.alivecor.com.
AliveCor is a trademark of AliveCor, Inc., registered in the U.S. and other countries
About LifeWatch AG:
LifeWatch AG, headquartered in Zug and listed on SIX Swiss Exchange (LIFE), Switzerland, is a leading healthcare technology and solution company, specializing in advanced digital health systems and wireless remote diagnostic patient monitoring services. LifeWatch’s services provide physicians with critical information to determine appropriate treatment and thereby improve patient outcomes. LifeWatch AG has operative subsidiaries in the United States, in Switzerland and in Israel, and is the parent company of LifeWatch Services Inc., and LifeWatch Technologies, Ltd. LifeWatch Services, Inc. is a leading U.S.-based provider of cardiac monitoring services and home sleep testing of Obstructive Sleep Apnea (OSA). LifeWatch Technologies Ltd., based in Israel, is a leading developer and manufacturer of telemedicine products. For additional information, please visit www.lifewatch.com.